Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
Amazon Secures 200 MW Wind Power Deals in Sweden 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Add as a preferred source on Google
NEW YORK, April 05, 2018 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Solid Biosciences Inc. ("Solid Biosciences") (NASDAQ:SLDB) pursuant to the January 25, 2018 initial public offering and/or between January 25, 2018 and March 14, 2018. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Massachusetts. To get more information go to:
http://www.zlk.com/pslra-d/solid-biosciences-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Solid Bioscience’s lead drug candidate, SGT-001, had a high likelihood of causing adverse events in patients; (2) the company misled investors regarding the toxicity of SGT-001; and (3) consequently, defendants’ statements in the Registration Statement regarding Solid Biosciences’ business, operations, and prospects were materially false and/or misleading.
If you suffered a loss in Solid Biosciences you have until May 29, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
